glp-1 and afib If you take a medication to help manage your weight or blood sugar also have a heart rhythm condition called atrial fibrillation (Afib), a new study from UVA Health offers GLP-1 Agonists in Cardiovascular Diseases:

Description

Three million members of CVS Caremarks clients now enjoy access to clinical weight loss program with proven results, high satisfaction WOONSOCKET, R.I., March 14, 2025 CVS Health (NYSE: CVS) released compelling data today from the CVS Weight Management TM program in which participants achieved more than 15% weight loss on average, including existing anti-obesity medication users who succeeded in nearly doubling their pre-program weight loss while working with program clinicians on diet and lifestyle.* Before enrolling in the CVS Weight Management program, 70% of members were using a weight management drug without any lifestyle or nutrition support.* The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients' plan members trying a lifestyle-first approach and additional clinical effectiveness and cost savings for members receiving clinical support while taking weight management medications like GLP-1s

$LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes More Info: pryzm.ozmosi.com/product/18435 $LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes More Info: pryzm.ozmosi.com/product/18435

In most cases, wegovy and hair loss, mounjaro and hair loss, or tirzepatide hair loss are not caused directly by the drug

Mancini GBJ, Cheng AY, Connelly K, et al

The next phase of GLP-1 development will no longer be defined by companies capability to develop the drug but their ability to develop systems that can consistently and reliably produce them at scale